ZEAL Zealand Pharma A/S

+0.11  (+1%)
Previous Close 13.09
Open 13.38
Price To Book 2.14
Market Cap 405168773
Shares 30,694,604
Volume 2,337
Short Ratio
Av. Daily Volume 7,952

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated September 2018.
Congenital hyperinsulinism
Phase 3 data released September 18, 2018. Endpoints met.
Severe hypoglycemia in diabetes
Phase 3 trial met primary endpoint - March 2018.
Severe hypoglycemia in diabetes
Phase 3 trial initiation announced October 4, 2018.
Short bowel syndrome
Phase 3 data 1H 2019.
Severe hypoglycemia in diabetes - children
Phase 2b trial to be completed 1H 2019.
Dasiglucagon dual-hormone pump therapy

Latest News

  1. Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
  2. Financial calendar for Zealand Pharma in 2019
  3. Zealand Pharma announces change in Executive Management
  4. Investor Expectations to Drive Momentum within Atomera, YogaWorks, Cellect Biotechnology, Eyegate Pharmaceuticals, Zealand Pharma A/S, and Polar Power — Discovering Underlying Factors of Influence
  5. Zealand Pharma - Interim report for the first nine months of 2018
  6. Zealand Pharma to attend Jefferies and Bryan, Garnier & Co Healthcare Conferences
  7. Zealand hosts conference call on November 15 at 4 pm CET (10 am EST) to present third quarter results for 2018
  8. Zealand announces amendments to its Articles of Association following the granting of warrants
  9. Zealand Pharma enrolls first patient in Phase 3 trial with glepaglutide for the treatment of short bowel syndrome
  10. Zealand Pharma expands leadership team and appoints Marino Garcia as Senior Vice President of Corporate & Business Development
  11. Total number of shares and voting rights in Zealand Pharma at September 28, 2018
  12. Zealand Pharma has initiated the Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia in children
  13. Zealand Pharma achieves primary and key secondary endpoints in pivotal Phase 3 trial with dasiglucagon for severe hypoglycemia